CANTON (June 19, 2025) – MMS, a global, data-focused clinical research organization (CRO), has been named the winner of the 2025 Fierce CRO Award in the category of Excellence in Client Service and Partnership and the company’s CEO Dr. Uma Sharma has earned the CRO Champion Award, which recognizes leaders whose vision and values have shaped the future of clinical development.
Judged on innovation and impact, measurable outcomes, and scalability, MMS was selected as the top organization demonstrating a powerful commitment to building collaborative, long-term sponsor relationships.
“We are thrilled to be named the top CRO in two categories, and this is directly correlated to the trust that our clients place in us,” said Dr. Sharma. “At MMS, scientific integrity and client trust are inseparable. Together, they form the backbone of the long-standing partnerships we’re proud to cultivate across the globe. From large pharmaceutical sponsors to emerging biotech, we are honored to support them through the constantly evolving challenges of development and regulatory approvals. This award belongs to every global #OneMMS team member who brings our values to life.”
What Sets MMS Apart in Client Service
MMS serves as an extension
of its clients by leveraging its science and data-focused colleagues,
processes, and platforms, including AI, in a way that fosters adaptability and enhances
continuous innovation, speed and quality. Highlights of its approach
include:
“Winning the
Excellence in Client Service award and having Uma named CRO Champion validates
the micro-decisions and care we put into every sponsor relationship,” said Ben
Dudley, Chief Commercial Officer at MMS. “In today’s increasingly complex R&D
environment, our team’s focus on responsiveness, scientific depth, and
proactive planning is truly making a difference, and we’re thankful that the
industry is recognizing our approach firsthand today.”
MMS continues to expand
its offerings, recently integrating KerusCloud®, a cloud-based statistical
modeling platform, and enhancing its end-to-end REMS services through
proprietary technology and regulatory leadership. These advancements, coupled
with the company’s commitment to excellence, demonstrate how MMS continues to
lead in service, science, and strategic partnerships.
To learn more
about MMS and its global services, visit www.mmsholdings.com, and see the full list
of winners and finalists at https://www.fiercebiotech.com/book/fierce-cro-awards.
About MMS MMS Holdings (MMS) is an award-winning, data-focused clinical
research organization (CRO) that supports the pharmaceutical and biotech
industries with a proven, scientific approach to complex trial data and
regulatory submission challenges. Strong industry experience, a 19-year track
record, AI technology-enabled services, and a data-driven approach to drug
development make MMS a valuable CRO partner. With a global footprint across
four continents, MMS maintains an industry-leading customer satisfaction
rating. For more information, visit www.mmsholdings.com.
Media Contacts Don F. McLean, dmclean1@mmsholdings.com +1-734-716-4182
